Candesartan cilexetil: An angiotensin II receptor blocker

Annals of Pharmacotherapy

Volumn 33, Issue 12, 1999, Pages 1287-1298

  Stoukides, Cheryl A ^a,b   McVoy, Heather J ^c   Kaul, Alan F ^a  

^a Medical Outcomes Management Inc   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

AngIotensin II receptor blocker; Candesartan cilexetil; Congestive heart failure; Hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR; CANDESARTAN HEXETIL; ENALAPRIL; HYDROCHLOROTHIAZIDE; LOSARTAN;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; HYPERTENSION; META ANALYSIS; PRIORITY JOURNAL; REVIEW;

EID: 0033390259     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19005     Document Type: Review

References (72)

1. The Sixth Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46.
2. Sever PS. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. J Hum Hypertens 1997;11(suppl):S91-5.
3. Karlberg BE. Cough and inhibition of the renin-angiotensin system. J Hypertens Suppl 1993;11:S49-52.
4. 1 receptor. Eur J Pharmacol 1997;319:137-46.
5. Flesch M, Ko Y, Seul C, Düsing R, Feltkamp H, Vetter H, et al. Effects of TCV-116 and CV-11974 on angiotensin II-induced responses in vascular smooth muscle cells. Eur J Pharmacol 1995;289:399-402.
6. Kondo T, Yoshida K, Yoshimura Y, Motohashi M, Tanayama S. Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs. Arzneimittelforschung 1996;46:594-600.
7. Sachinidis A, el-Haschimi K, Ko Y, Seul C, Düsing R, Vetter H. CV-11974, the active metabolite of TCV-116 (candesartan), inhibits the synergistic or additive effect of different growth factors on agiotensin II-induced proliferation of vascular smooth muscle cells. Biochem Pharmacol 1996;52:123-6.
8. 1) receptor gene expression in primarily cultured human arterial umbilical endothelial cells. Biochem Pharmacol 1997;53: 417-21.
9. 1 receptor blockade by candesartan on arterial pressure and renal function in rats. Am J Physiol 1998;274(suppl):F940-5.
10. Nakamura T, Obata JE, Onizuka M, Kimura H, Ohno S, Yoshida Y, et al. Candesartan prevents the progression of mesangioproliferative nephritis in rats. Kidney Int 1997;52(suppl):S226-8.
11. Noda M, Fukuda R, Matsuo T, Ohta M, Nagano H, Imura Y, et al. Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats. Kidney Int 1997;52(suppl):S136-9.
12. Obata JE, Nakamura T, Kuroyanagi R, Yoshida Y, Guo DF, Inagami T. Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats. Kidney Int 1997;52(suppl):S229-31.
13. Mackenzie HS, Ziai F, Nagano H, Azuma H, Troy JL, Rennke HG, et al. Candesartan cilexetil reduces chronic renal allograft injury in Fisher→ Lewis rats. J Hypertens 1997;15(suppl):S21-5.
14. Garrison EA, Champion HC, Kadowitz PJ. [Pro11, D-Ala12]angiotensin 1 has rapid onset vasoconstrictor activity in the cat. Am J Physiol 1997; 273:E1059-64.
15. Champion HC, Kadowitz PJ. Analysis of the effects of candesartan in the mesenteric vascular bed of the cat. Hypertension 1997;30:1260-6.
16. 1 receptors in the rat. Am J Physiol 1998;274: E115-23.
17. Lambert DG, Champion HC, Kadowitz PJ. Inhibitory effects of candesartan on responses to angiotensin peptides in the hindquarters vascular bed of the cat. Can J Physiol Pharmacol 1998;76:133-40.
18. 1-receptor antagonist, in conscious spontaneously hypertensive rats. Jpn J Pharmacol 1997;73:185-90.
19. Wada T, Sanada T, Ojima M, Kanagawa R, Nishikawa K, Inada Y. Combined effects of the angiotensin II antagonist candesartan cilexetil (TCV-116) and other classes of antihypertensive drugs in spontaneously hypertensive rats. Hypertens Res 1996;19:247-54.
20. Prescribing information. Atacand (candesartan cilexetil). Wayne, PA: AstraZeneca Pharmaceuticals LP, 1998.
21. 1B receptors in blood pressure regulation. Am J Physiol 1997;272(4, pt 2):F515-20.
22. Weber MA. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension. J Hypertens 1997;15(suppl):S31-6.
23. Nishikawa K, Naka T, Chatani F, Yoshimura Y. Candesartan cilexetil: a review of its preclinical pharmacology. J Hum Hypertens 1997;11(suppl 2):S9-17.
24. van Lier JJ, van Heiningen PN, Sunzel M. Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers. J Hum Hypertens 1997;11(suppl 2):S27-8.
25. Belz GG, Fuchs B, Malerczyk C, Magin SG, Roll S, Mutschler E. Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers. J Hum Hypertens 1997;11(suppl 2):S45-7.
26. Johnston CI, Naitoh M, Burrell LM. Rationale and pharmacology of angiotensin II receptor antagonists: current status and future issues. J Hypertens 1997;15(suppl7):S3-6.
27. Menard J, Chaterllier G, Azizi M. Do we need angiotensin II antagonists to treat hypertensive patients? J Hum Hypertens 1997;11(suppl 2):S1-7.
28. Malerczyk C, Fuchs B, Belz GG, Roll S, Bulzer R, Breithaupt-Grögler K, et al. Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man. Br J Clin Pharmacol 1998;45:567-73.
29. Hübner R, Högemann AM, Sunzel M, Riddell JG. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997;11(suppl 2):S19-25.
30. Riddell JG. Bioavailability of candesartan is unaffected by food in healthy volunteers administered candesartan cilexetil. J Hum Hypertens 1997;11(suppl 2):S29-30.
31. Meineke I, Feltkamp H, Högemann A, Gundert-Remy U. Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension - a population analysis. Eur J Clin Pharmacol 1997;53: 221-8.
32. de Zeeuw D, Remuzzi G, Kirch W. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. J Hum Hypertens 1997;11(suppl 2):S37-42.
33. Hoogkamer JF, Kleinbloesem CH, Ouwerkerk M, Högemann A, Nokhodian A, Kirch W, et al. Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function. Eur J Clin Pharmacol 1998;54:341-5.
34. Jonkman JH, van Lier JJ, van Heiningen PN, Lins R, Sennewald R, Högemann AM. Pharmacokinetic drug interaction studies with candesartan cilexetil. J Hum Hypertens 1997;11(suppl 2):S31-5.
35. Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. Br J Pharmacol 1959;14:48-58.
36. Fridman K, Andersson OK, Wysocki M, Friberg P. Effects of an acute dose of 16 mg candesartan cilexetil on systemic and renal haemodynamics in hypertensive patients. J Hum Hypertens 1997;11(suppl 2):S43-4.
37. Fridman K, Andersson OK, Wysocki M, Friberg P, Sunzel M. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients. Eur J Clin Pharmacol 1998;54:497-501.
38. Kawabata M, Takabatake T, Ohta H, Nakamura T, Hara H, Ohta K, et al. Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension. Blood Press 1994;3(suppl 5):117-21.
39. Buter H, Navis G, de Zeeuw D, De Jong PE. Renal hemodynamic effects of candesartan in normal and impaired renal function in humans. Kidney Int 1997;52:5185-7.
40. Belcher G, Hübner R, George M, Elmfeldt D, Lunde H. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1997;11(suppl 2):S85-9.
41. McInnes GT, O'Kane KP, Jonker J, Roth J. The efficacy and tolerability of candesartan cilexetil in an elderly hypersensive population. J Hum Hypertens 1997;11(suppl 2):S75-80.
42. Sever PS, Holzgreve H. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997;11(suppl 2):S69-73.
43. Elmfeldt D, George M, Hübner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997;11(suppl 2):S49-53.
44. Heuer HJ, Schöndorfer G, Högemann AM. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997;11(suppl 2):S55-6.
45. Andersson OK. Tolerability of a modern antihypertensive agent: candesartan cilexetil. Basic Res Cardiol 1998;93(suppl 2):54-8.
46. Naeshiro I, Sato K, Chatani F, Sato S. Possible mechanism for the anemia induced by candesartan cilexetil (TCV-116), an angiotensin II receptor antagonist, in rats. Eur J Pharmacol 1998;354:179-87.
47. Perish RC, Miller LJ. Adverse effects of an angiotensin converting enzyme (ACE) inhibitor. Drug Saf 1992;7:14-31.
48. Ducloux D, Chalopin JM. Losartan decreases hemoglobin in renal transplant recipients. Transplant Proc 1997;29:2402-3.
49. Ozbek N, Ozen S, Saatci U. Enalapril-induced anemia in a renal transplant patient. Acta Paediatr Jpn 1997;39:626-7.
50. Shand BI. Effects of losartan on haematology and haemorrheology in elderly patients with essential hypertension. J Hum Hypertens 1995;9:233-5.
51. Fyhrquist F. High serum erythropoietin levels are normalized during treatment of congestive heart failure with enalapril. J Intern Med 1989; 226:257-60.
52. Reif M, White WB, Fagan TC, Oparil S, Flanagan TL, Edwards DT, et al., for the Candesartan Cilexetil Study Investigators. Effects of candesartan cilexetil in patients with systemic hypertension. Am J Cardiol 1998;82:961-5.
53. Hübner R, Elmfeldt D, George M, Olofsson B. Candesartan cilexetil, a novel angiotensin II antagonist, provides dose dependent antihypertensive effect with maintained tolerability (abstract). Am J Hypertens 1997; 10:(4, pt 2):87A.
54. O'Kane KP, Fridman K, Mclnnes G. Tolerability and efficacy of candesartan cilexetil 32 mg once daily in hypertensive patients. Am J Hypertens 1997;15(suppl 4):S174.
55. O'Kane KPJ, Fridman K, McInnes G. Tolerability and efficacy of candesartan cilexetil 32 mg once daily in hypertensive patients (abstract). Am J Hypertens 1997;10(4, pt 2): 111A.
56. Bart B, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau J, et al. Contemporary management of patients with left ventricular dysfunction: preliminary results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) registry (abstract). Eur Heart J 1997;18:402.
57. Granger CB, Kuch J, McMurray J, Rouleau J, Swedberg K, Young J, et al., on behalf of the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Investigators. A randomized trial evaluating tolerability of candesartan cilexetil for patients with congestive heart failure and intolerance to angiotensin converting enzyme inhibitors (abstract). Eur Heart J 1998;19(suppl 1):133.
58. Andersson OK, Neldam S. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension. J Hum Hypertens 1997;11(suppl 2):S63-4.
59. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998;7:53-9.
60. Franke H. Antihypertensive effects of candesartan cilexetil, enalapril and placebo. J Hum Hypertens 1997;11(suppl 2):S61-2.
61. Zanchetti A, Omboni S, Di Biagio C. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension. J Hum Hypertens 1997;11(suppl 2):S57-9.
62. Tsuyuki RT, Yusuf S, Rouleau JL, Maggioni AP, McKelvie RS, Wiecek EM, et al. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol 1997; 13:1166-74.
63. Tsuyuki RT, Yusuf S, Wiecek EM, Rouleau J, White M, Koon TK, et al. Combined neurohormonal blockade with ACE inhibitors, angiotensin-II blockers, and beta blockers: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study (abstract). Can J Cardiol 1996;12(suppl E):102E.
64. Philipp T, Letzel H, Arens HJ. Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. J Hum Hypertens 1997;11(suppl 2):S67-8.
65. Plouin PF. Combination therapy with candesartan cilexetil plus hydrochlorothiazide in patients unresponsive to low-dose hydrochlorothiazide. J Hum Hypertens 1997;11(suppl 2):S65-6.
66. Farsang C, Kawecka-Jaszcz K, Langan J, Maritz F, Zannad F. Antihypertensive effects and tolerability of candesartan cilexetil, amlodipine and their combination (abstract). Am J Hypertens 1997;10:80A.
67. MacGregor GA, Antonios TFT, HE FJ, on behalf of the UK and Israel Candesartan Investigators. The efficacy of candesartan cilexetil: an angiotensin II type I receptor antagonist alone or in combination with amlodipine or in combination with amlodipine and hydrochlorothiazide in patients with moderate to severe essential hypertension (abstract). J Hum Hypertens 1998;11:617.
68. Trenkwalder P, Lehtovirta M, Dahl K. Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes. J Hum Hypertens 1997;11(suppl 2):S81-3.
69. Trenkwalder P. Effects of candesartan on glucose homeostasis. Basic Res Cardiol 1998;93(suppl 1):140-4.
70. Belcher G, Hübner R, George M, Elmfeldt D, Lunde H. Safety and tolerability of candesartan cilexetil in the elderly. Am J Hypertens 1998;16 (suppl 2):S249.
71. Drug topics red book. Montvale, NJ: Medical Economics Data, 1999.
72. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.